Key Ideas

Capivasertib, an oral AKT inhibitor approved for hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer with PIK3CA, AKT1, or PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy, carries a labeled risk of hyperglycemia requiring a structured, front-loaded monitoring schedule. A real-world case illustrates how gaps in that schedule, a missed lab draw, a patient unable to return to clinic, can allow glucose to climb into a dangerous range before it is caught, underscoring the case for equipping select patients with a home glucometer from day one.

A Case That Surfaced a Monitoring Gap

A woman in her fifties with hormone receptor-positive, HER2-negative, PIK3CA-altered metastatic breast cancer, following progression on an endocrine-based regimen, began standard-dose capivasertib on its labeled 400 mg twice daily for 4 consecutive days, followed by 3 days off dosing. Given a relevant history of type 2 diabetes and a baseline fasting glucose of 142 mg/dL with an HbA1c of 6.4%, metformin 500 mg daily was started concurrently.

Glucose values fluctuated over the following weeks, though documentation of whether readings were fasting was inconsistent, a gap worth flagging for any patient starting this medication. At week four, a scheduled laboratory check was missed due to a lab collection error, and the patient then sustained a foot injury that prevented her from returning to clinic. By the time she was seen again, at week five, her fasting glucose had risen to 494 mg/dL. Capivasertib was held, metformin was increased to twice-daily dosing, and glucose improved to 178 mg/dL within a week; the patient was also started on home glucometer self-monitoring at this point, a step that, in retrospect, might have caught the rising trend before it reached a critical level. After glucose remained consistently below 160 mg/dL for a month, capivasertib was resumed at a reduced dose of 320 mg twice daily on the same four-days-on, three-days-off schedule.

Why the Labeled Monitoring Schedule Is Unusually Demanding

Capivasertib's labeled monitoring requirements are more front-loaded than those of many oral targeted therapies: fasting glucose checks on day 3 or 4 of the dosing week during weeks 1, 2, 4, 6, and 8, transitioning to monthly checks thereafter, along with a hemoglobin A1c every three months. In the pivotal CAPItello-291 trial, increased fasting glucose occurred in roughly one-third of patients, with a median time to onset of approximately two weeks, and about 12% of patients required initiation or modification of anti-diabetic medication. Notably, the trial excluded patients with type 1 diabetes and insulin-dependent type 2 diabetes, so safety data are not available for those populations, and this medication does not have a well-established profile in them.

The schedule's frequency, once weekly during the highest-risk early weeks, creates an access barrier, particularly for patients who live far from an infusion or clinic site. This is not a minor logistical detail: in the case described here, the gap created by a missed scheduled lab combined with an unrelated injury preventing clinic return was precisely what allowed glucose to climb unmonitored into a range associated with diabetic ketoacidosis risk.

Management Thresholds by Glucose Range

Recommendations for managing hyperglycemia scale with severity. Once fasting glucose exceeds the upper limit of normal or HbA1c exceeds 7%, initiating or intensifying metformin is the first step, typically before any dose modification of capivasertib itself. At a fasting glucose of 161 to 250 mg/dL, therapy is withheld until glucose returns to 160 mg/dL or below; recovery within 28 days allows resumption at the same dose, while recovery beyond 28 days calls for resumption at the next lower dose tier. At 251 to 500 mg/dL, the same withhold-and-reassess approach applies, but resumption only occurs at a reduced dose if recovery occurs within 28 days. If recovery extends beyond 28 days, the package insert recommends permanent discontinuation of capivasertib. For life-threatening hyperglycemia, permanent discontinuation is recommended. Standard dose reduction tiers proceed from the labeled 400 mg twice daily to 320 mg twice daily, then to 200 mg twice daily, with the four-days-on, three-days-off schedule preserved at each step; inability to tolerate the second reduction warrants permanent discontinuation.

The Case for Proactive Self-Monitoring

For any patient starting capivasertib, and particularly those with existing diabetes risk factors, equipping the patient with a glucometer at treatment initiation, rather than only after a hyperglycemic event has already occurred, deserves consideration as a default management strategy. This does not need to replace in-clinic monitoring, but it provides a safety net for exactly the scenario that occurred here: an unrelated life event that prevents a scheduled clinic visit during the highest-risk early weeks of treatment. Not every patient will have the interest or health literacy to use a glucometer effectively, but for those who do, it closes the gap in a monitoring schedule that otherwise depends entirely on the patient's ability to physically return to clinic on a demanding weekly cadence.

For Patients

Capivasertib is an oral targeted therapy used for certain types of hormone receptor-positive, HER2-negative metastatic breast cancer with specific genetic changes in the tumor and following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. One of its most common side effects is a rise in blood sugar, which is why this medication comes with a strict monitoring schedule, especially in the first two months of treatment.

If you are prescribed capivasertib, ask your care team about checking your blood sugar at home with a glucometer from the very start of treatment, particularly if getting to the clinic every week is difficult for any reason, including distance, work schedule, or an unrelated injury or illness. Report any symptoms of high blood sugar, such as excessive thirst, frequent urination, or unusual fatigue, right away rather than waiting for your next scheduled check. If your blood sugar does rise significantly, your care team has clear, established steps for adjusting your diabetes medication and your capivasertib dose to bring it back under control safely.

Key Takeaways

  • Capivasertib's labeled monitoring schedule requires fasting glucose checks on day 3 or 4 of weeks 1, 2, 4, 6, and 8, then monthly, plus HbA1c every three months, one of the more demanding schedules among oral targeted therapies.

  • In CAPItello-291, increased fasting glucose occurred in roughly one-third of patients, with median onset around two weeks; the trial excluded type 1 diabetes and insulin-dependent type 2 diabetes, leaving a safety data gap for those populations.

  • Management escalates by glucose range and timeframe to resolution of blood glucose to 160 mg/dL or less: metformin initiation or intensification for blood glucose above the upper limit of normal, treatment hold and reassessment at 161 to 250 mg/dL with dose reduction if greater than 28 days to resolution, dose reduction on resumption at 251 to 500 mg/dL if resolution within 28 days or less, and permanent discontinuation for 251 to 500 mg/dL if no recovery within 28 days or for life-threatening hyperglycemia.

  • A missed scheduled lab draw combined with an unrelated inability to return to clinic allowed glucose to reach 494 mg/dL in this case before it was caught.

  • Proactively equipping appropriate patients with a home glucometer at treatment initiation, rather than only after a hyperglycemic event, may close a gap created by the schedule's demanding weekly cadence. This could allow for earlier management of hyperglycemia and subsequent resumption of treatment, potentially resulting in less treatment interruptions as a whole. 

References

  1. Truqap (capivasertib) prescribing information. AstraZeneca Pharmaceuticals LP.

  2. Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058-2070.

  3. Rugo HS, Oliveira M, Dalenc F, et al. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study. ESMO Open. 2024;9(9):103697.